Systems modeling identifies phenotype-determining signaling pathways controlled by phosphatase PTPRJ in diverse...

Protein tyrosine phosphatase receptor J (PTPRJ) restrains cell proliferation and migration by dephosphorylating receptor tyrosine kinases (RTKs) including the epidermal growth factor receptor (EGFR). PTPRJ is a purported tumor suppressor, and alterations to its expression and/or function are associated with colorectal, breast, lung, and other cancers. While there is interest in controlling PTPRJ-regulated phenotypes, efforts are limited by the complexity of PTPRJ-mediated signaling. PTPRJ dephosphorylates multiple RTKs, and the degree to which PTPRJ control of signaling and phenotypes depends on local cellular RTK activation profiles is unknown. To probe the context dependence of PTPRJ signaling regulation, we collected signaling measurements across 16 pathway nodes at two time points in a panel of HSC3 carcinoma cells engineered with different PTPRJ expression profiles. Cells were treated with three different RTK ligands, and paired phenotype measurements (viability, wound healing, xCELLigence cell index) were made. Partial least squares regression models were developed to predict relationships between PTPRJ-regulated signaling pathways and cell phenotypes. The model effectively separated contributions to variance arising from the PTPRJ expression background and growth factor context. In testing model predictions, we demonstrated that PTPRJ suppressed MET-induced cell cell proliferation via regulation of a HER3/AKT signaling axis that stabilized PTPRJ expression through an unanticipated feedback mechanism. We also found that PTPRJ regulated HSC3 cell migration via JNK signaling that was preferentially activated by MET. Our results identify new regulatory nodes through which PTPRJ influences cancer cell phenotypes and demonstrates that these processes preferentially occur in the context of distinct RTK activation states.